.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Federal Trade Commission
Chinese Patent Office
Queensland Health
Covington
Fish and Richardson
Harvard Business School
US Army
UBS
Merck

Generated: June 29, 2017

DrugPatentWatch Database Preview

MECAMYLAMINE HYDROCHLORIDE Drug Profile

« Back to Dashboard

What is the patent landscape for Mecamylamine Hydrochloride, and when can generic versions of Mecamylamine Hydrochloride launch?

Mecamylamine Hydrochloride is a drug marketed by Nexgen Pharma and is included in one NDA.

The generic ingredient in MECAMYLAMINE HYDROCHLORIDE is mecamylamine hydrochloride. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the mecamylamine hydrochloride profile page.

Summary for Tradename: MECAMYLAMINE HYDROCHLORIDE

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list28
Clinical Trials: see list2,268
Patent Applications: see list345
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:MECAMYLAMINE HYDROCHLORIDE at DailyMed

Pharmacology for Tradename: MECAMYLAMINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nexgen Pharma
MECAMYLAMINE HYDROCHLORIDE
mecamylamine hydrochloride
TABLET;ORAL204054-001Mar 19, 2013RXNoYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Cipla
Chubb
Deloitte
Johnson and Johnson
McKinsey
Dow
Express Scripts
Harvard Business School
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot